Utilization Evaluation of Human Papilloma Virus Vaccine (GARDASIL®) In Iran; A Cross-Sectional Study.

Document Type : Research article

Authors

1 Research Center for Rational Use of Drugs, Tehran University of Medical Sciences,Tehran,Iran.

2 Research Center for Rational Use of Drugs. Tehran University of Medical Sciences,Tehran.

3 Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.

4 Faculty of Pharmacy, Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Vaccination against HPV seems to be a good approach for prevention of cervical cancer and genital warts. But in Iran we are confronted with lack of evidence for its cost-effectiveness whereas its consumption is dramatically increasing.
This was a cross- sectional study. We used a questionnaire included 5 sections as follows; Patients demographic information, Patients medical history, Pregnancy and lactation considerations, Gardasil prescription characteristics and HPV infection characteristics. Prescriber with adherence to guideline were defined as those prescribing Gardasil for correct age range and indication with accurate dosage and administration. Descriptive statistics for variables was shown by frequency (percent) or mean (±SD) and evaluation of relation between categorical variables was performed by using Chi-square test.
Total 566 Gardasil recipients participated in the study. There were mostly female with mean age of 28.1 (±6.68). For 128 (22.6%) participants Gardasil prescribed correctly considering both age range (9-26 years) and indication (prophylactic). From this group, 80 participants (14.1%/566) have received accurate Gardasil dosage and interval (prescriber had adherence to guideline). Patients’ out of pocket payment in guidelines adherent prescriptions was a seventh of total costs obtained from 566 consumers. Gynecologists significantly prescribed for prophylaxis higher than other specialties (p-value=0.01).
Prescribers’ practice in administrating Gardasil is obviously not appropriate and it is imposing burdensome cost to community and government. On the other hand we encounter with increase rate of use in Iran for past years. Therefor we are in urgent need for appropriate interventions in national level and prompt supervision to regulate Gardasil consumption.

Graphical Abstract

Utilization Evaluation of Human Papilloma Virus Vaccine (GARDASIL®) In Iran; A Cross-Sectional Study.

Keywords

Main Subjects



1. Harper DM, Vierthaler SL and Santee JA. Review ofgardasil. J. Vaccines. Vaccin. (2010) 1: 107.
2. Gizzo S, Noventa M and Nardelli GB. Gardasiladministration to hr-HPV-positive women and theirpartners. Trends. Pharmacol. Sci. (2013) 34: 479-80.
3. Khorasanizadeh F, Hassanloo J, Khaksar N, TaheriSM, Marzaban M, Rashidi BH, Sari AA andZendehdel K. Epidemiology of cervical cancer andhuman papilloma virus infection among Iranianwomen - analyses of national data and systematicreview of the literature. Gynecol. Oncol. (2013) 128:277-81.
4. Franco EL and Harper DM. Vaccination againsthuman papillomavirus infection: a new paradigm incervical cancer control. Vaccine. (2005) 23: 2388-94.
5. Khatibi M, Rasekh HR, Shahverdi Z and JamshidiHR. Cost-effectiveness evaluation of quadrivalenthuman papilloma virus vaccine for hpv-relateddisease in Iran. Iran. J. Pharm. Res. (2014) 13: 225-34.
6. Markowitz LE, Dunne EF, Saraiya M, ChessonHW, Curtis CR, Gee J, Bocchini Jr JA andUnger ER. Human Papillomavirus Vaccination 76Gardasil Utilization Evaluation in Iran Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR.Recomm. Rep. (2014) 63(RR-05): 1-30.
7. Kirby T. FDA approves new upgraded Gardasil 9.Lancet. Oncol. (2015) 16: e56.
8. Braaten KP and Laufer MR. Human Papillomavirus(HPV), HPV-Related Disease, and the HPV Vaccine.Rev. Obstet. Gynecol. (2008) 1: 2-10.
9. Jalilvand S, Shoja Z, Nourijelyani K, Tohidi HR andHamkar R. Meta-analysis of type-specific humanpapillomavirus prevalence in Iranian women withnormal cytology, precancerous cervical lesions andinvasive cervical cancer: Implications for screeningand vaccination. J. Med. Virol. (2015) 87: 287-95.
10. Castellsague X, de Sanjose S, Aguado T, LouieKS, Bruni L, Munoz J, Diaz M, Irwin K, GacicM, Beauvais O, Albero G, Ferrer E, Byrne S andBosch FX. HPV and Cervical Cancer in the World: 2007 Report. Vaccine (2007) 1: C1-C230.11. Mazza D, Petrovic K, Grech C and Harris N. HPVvaccination in women aged 27 to 45 years: what do general practitioners think? BMC. Women. health.(2014) 14: 91.
12. Dempsey AF and Patel DA. HPV vaccine acceptance,utilization and expected impacts in the US: Where arewe now? Hum. Vaccin. (2010) 6: 715-20.
13. Highlights of prescribing information,available at https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/pprovedproducts/ucm111263.pdf. date of access data: 4.29.2017.
14. Fagot J-P, Boutrelle A, Ricordeau P, Weill A andAllemand H. HPV vaccination in France: uptake,costs and issues for the National Health Insurance.Vaccine (2011) 29: 3610-6.
15. Dunne EF, Markowitz LE. Genital humanpapillomavirus infection. Clin. Infect. Dis. (2006)43: 624-9.
16. Insinga RP, Dasbach EJ, Allen SE, Carides GW andMyers ER. Reductions in Human PapillomavirusDisease Resource Use and Costs with QuadrivalentHuman Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE StudyEconomic Evaluation. Value Health ( 2008) 11:
1022-32.
17. Garland SM, Hernandez-Avila M, Wheeler CM,Perez G, Harper DM, Leodolter S, Tang GW,Ferris DG, Steben M, Bryan J, Taddeo FJ, RailkarR, Esser MT, Sings HL, Nelson M, Boslego J,Sattler C, Barr E and Koutsky LA. Quadrivalentvaccine against human papillomavirus to preventanogenital diseases. N. Engl. J. Med. (2007) 356:1928-43.
18. Shafaghi B, Jarollahi A, Yousefzadeh B, Ameri A,Moghadam S and Mostafavi M. Human PapillomaVirus Prevalence and Types among Iranian WomenAttending Regular Gynecological visits. Rep.Radiothe. Oncol. (2013) 1: 73-79.
19. Brotherton JM, Gertig DM, May C, Chappell Gand Saville M. HPV vaccine impact in Australianwomen: ready for an HPV-based screeningprogram. Med. J. Aust. (2016) 204: 184-184e1
20. Bryan JT, Buckland B, Hammond J and JansenKU. Prevention of cervical cancer: journey todevelop the first human papillomavirus virus-likeparticle vaccine and the next generation vaccine.Curr. Opin. Chem. Biol. (2016) 32: 34-47.
21. Villa J, Muñoz N, Perez G, Krüger Kjaer S,Paavonen J, Lehtinen M, Sigurdsson K, HernandezAvila M, Iversen OE, García P, Majewski S, TayEH, Bosch FX, Dillner J, Olsson SE, Ault K,Brown D, Ferris D, Koutsky L, Kurman R, MyersE, Barr E, Bryan J, Boslego J, Esser M, Hesley T,Lupinacci L, Railkar R, Saah A, Sattler C, TaddeoF, Thornton A and Vuocolo S. Prophylactic efficacyof a quadrivalent human papillomavirus (HPV)vaccine in women with virological evidence ofHPV infection. J. Infect. Dis. (2007) 196: 1438-46.
22. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MCand Zanini RR. Efficacy of human papillomavirusvaccines: a systematic quantitative review. Int. J.Gynecol. Cancer. (2009) 19: 1166-76.
23. Dempsey A, Cohn L, Dalton V and Ruffin M.Patient and clinic factors associated with adolescenthuman papillomavirus vaccine utilization within auniversity-based health system. Vaccine (2010) 28:989-95.
24. Kessels SJ, Marshall HS, Watson M, BraunackMayer AJ, Reuzel R and Tooher RL. Factorsassociated with HPV vaccine uptake in teenagegirls: a systematic review. Vaccine (2012) 30: 3546-56.
25. Gerend MA, Shepherd MA and Shepherd JE.The multidimensional nature of perceivedbarriers: Global versus practical barriers to HPVvaccination. Health Psychol. (2013) 32: 361-9